Hepatocellular carcinoma (HCC) is a malignant disease with poor prognosis.[@b1-jhc-4-011] Its officially recommended treatment is by sorafenib therapy, which is extremely expensive, often causes adverse events, and prolongs overall survival by only 3 months in patients with advanced disease.[@b2-jhc-4-011],[@b3-jhc-4-011] Immunotherapy targeting programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) has shown impressive antitumor efficacy in several solid cancers,[@b4-jhc-4-011]--[@b6-jhc-4-011] including advanced HCC.[@b7-jhc-4-011] Since response rates of various cancers to such immunotherapy appear to correlate with PD-L1 expression levels,[@b8-jhc-4-011] several studies have examined whether PD-L1 expression correlates with HCC pathology and patient prognosis. As the results obtained were inconsistent, Gu et al[@b9-jhc-4-011] initiated to perform the first meta-analysis that focused on the associations of PD-L1 with HCC characteristics and patient prognosis.[@b9-jhc-4-011] They concluded that higher PD-L1 levels predict poor differentiation, vascular invasion, higher levels of α-fetoprotein (AFP), and poorer survival. While these results are clinically useful, they should be interpreted with several limitations in mind.

One of the limitations is that the meta-analysis did not include four studies[@b10-jhc-4-011]--[@b13-jhc-4-011] involving 384 patients that satisfied the inclusion criteria of this meta-analysis.[@b9-jhc-4-011] In addition, one study[@b14-jhc-4-011] included in this meta-analysis was based on PD-L1 assays in serum but not in tumor samples. The patients included in this study received both surgery and palliative therapies, while in other studies,[@b15-jhc-4-011]--[@b20-jhc-4-011] patients received only surgery. These issues may increase heterogeneity in the pooled data, undermining the reliability of the results. In addition, it is unclear to us how this meta-analysis was able to report survival hazard ratios for the pooled patient population with tumors of any stage, when most studies in the meta-analysis reported survival separately by tumor stages but not in the population as a whole.

The work of Gu et al[@b9-jhc-4-011] suggests that higher PD-L1 levels are associated with poorer clinicopathological characteristics of HCC. To extend this finding, we examined eleven studies and found that none of the studies reported gender, age, or hepatitis history to be associated with elevated PD-L1 expression ([Table 1](#t1-jhc-4-011){ref-type="table"}). Only one study associated high PD-L1 expression with higher preoperative serum levels of AFP, poor tumor differentiation, and satellite nodules;[@b10-jhc-4-011] two studies associated it with tumor size;[@b11-jhc-4-011],[@b20-jhc-4-011] four studies associated it with vascular invasion;[@b10-jhc-4-011],[@b16-jhc-4-011],[@b17-jhc-4-011],[@b20-jhc-4-011] and four studies[@b12-jhc-4-011]--[@b14-jhc-4-011],[@b20-jhc-4-011] associated it with tumor stage. One study reported no significant association between high PD-L1 levels and overall survival,[@b15-jhc-4-011] while another study reported a nonsignificant trend that higher levels were associated with shorter overall survival.[@b18-jhc-4-011]

The results in [Table 1](#t1-jhc-4-011){ref-type="table"} and those reported by Gu et al[@b9-jhc-4-011] suggest that elevated PD-L1 levels are associated with several HCC characteristics that are also risk factors for early tumor recurrence. Such recurrence can occur through two mechanisms: true metastasis due to primary HCC dissemination before surgery and multicentric occurrence (de novo) in remnant liver due to continuous viral infection and inflammation.[@b21-jhc-4-011] HCC treatments are usually effective against one or the other type of recurrence, but not both. In contrast, targeting PD-L1 may inhibit both types simultaneously, since reducing PD-L1 levels can strengthen T-cell responses to hepatitis virus infection.[@b22-jhc-4-011],[@b23-jhc-4-011]

Despite its limitations, the meta-analysis of Gu et al[@b9-jhc-4-011] substantially strengthens the evidence that higher PD-L1 levels are associated with poorer clinicopathological characteristics of HCC and poorer prognosis of patients. Further phase I or phase II clinical trials should be performed to investigate anti-PD-L1 treatment for HCC.
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###### 

Summary of studies examining potential associations of PD-L1 expression levels with HCC clinicopathological characteristics and patient prognosis

  Study                               Country                      Sample size   *P*-value                                                                                                                
  ----------------------------------- ---------------------------- ------------- ----------- -------- ------------ -------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Finkelmeier et al[@b14-jhc-4-011]   Germany                      215           NR          NR       NR           \>0.05   NR           NR           NR           NR           \<**0.05**   \<**0.05**   NR
  Gabrielson et al[@b15-jhc-4-011]    USA                          65            NR          NR       NR           \>0.05   \>0.05       NR           NR           \>0.05       \>0.05       0.353        NR
  Gao et al[@b16-jhc-4-011]           People's Republic of China   240           \>0.05      \>0.05   \>0.05       \>0.05   \>0.05       \>0.05       \>0.05       \<**0.05**   \>0.05       \<**0.05**   \<**0.05**
  Kan and Dong[@b17-jhc-4-011]        People's Republic of China   128           \>0.05      \>0.05   \>0.05       \>0.05   \>0.05       \>0.05       NR           \<**0.05**   \>0.05       \<**0.05**   NR
  Umemoto et al[@b18-jhc-4-011]       Japan                        80            \>0.05      \>0.05   \>0.05       \>0.05   \>0.05       \>0.05       \>0.05       \>0.05       \>0.05       0.051        0.081
  Wu et al[@b19-jhc-4-011]            People's Republic of China   71            NR          NR       NR           NR       NR           NR           NR           NR           NR           \<**0.05**   NR
  Zeng et al[@b20-jhc-4-011]          People's Republic of China   141           \>0.05      \>0.05   \>0.05       NR       NR           \<**0.05**   \>0.05       \<**0.05**   \<**0.05**   \<**0.05**   \<**0.05**
  Calderaro et al[@b10-jhc-4-011]     France                       217           \>0.05      \>0.05   \<**0.05**   \>0.05   \<**0.05**   \>0.05       \<**0.05**   \<**0.05**   NR           NR           \<**0.05**
  Jung et al[@b11-jhc-4-011]          Korea                        85            \>0.05      \>0.05   \>0.05       \>0.05   \>0.05       \<**0.05**   NR           \>0.05       \>0.05       \<**0.05**   \<**0.05**
  Shi et al[@b12-jhc-4-011]           People's Republic of China   56            NR          NR       NR           NR       NR           NR           NR           NR           \<**0.05**   NR           \<**0.05**
  Wang et al[@b13-jhc-4-011]          People's Republic of China   26            \>0.05      \>0.05   NR           \>0.05   \>0.05       NR           NR           NR           \<**0.05**   NR           NR

**Note:** Bold values are statistically significant.

**Abbreviations**: AFP, α-fetoprotein; DFS, disease-free survival; HCC, hepatocellular carcinoma; OS, overall survival; PD-L1, programmed death ligand 1; RFS, recurrence-free survival; NR, not reported.
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